Skip to main content
Top
Published in: Rheumatology International 5/2012

01-05-2012 | Original Article

Resolution of adalimumab-induced psoriasis after vitamin D deficiency treatment

Authors: Gláucio Ricardo Werner de Castro, Fabrício Souza Neves, Ivanio Alves Pereira, Sonia Cristina Magalhaes Souza Fialho, Giovana Ribeiro, Adriana Fontes Zimmermann

Published in: Rheumatology International | Issue 5/2012

Login to get access

Abstract

Tumoral necrosis factor alpha blockers are very efficient in the treatment of many inflammatory systemic diseases, including rheumatoid arthritis and psoriasis. However, a paradoxical arouse of psoriasiform lesions may occur in a few patients taking anti-TNFα. The etiology of this rare side effect is still a mystery, and its treatment may be difficult. The authors report the resolution of adalimumab-induced psoriasis in a woman with rheumatoid arthritis after the use of high vitamin D3 doses for the treatment of vitamin D deficiency. This is the first report of resolution of anti-TNFα-induced psoriasiform lesions by high doses of vitamin D3 in a patient with rheumatoid arthritis and vitamin D deficiency. This case raises interesting questions on the role of vitamin D deficiency in the pathogenesis of this side effect and on the possible usefulness of high-dose vitamin D3 in its treatment.
Literature
2.
go back to reference Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL et al (2009) Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis Fev 68(2):209–215CrossRef Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL et al (2009) Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis Fev 68(2):209–215CrossRef
3.
go back to reference Fouache D, Goëb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M et al (2009) Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford) 48(7):761–764CrossRef Fouache D, Goëb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M et al (2009) Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford) 48(7):761–764CrossRef
4.
go back to reference de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S et al (2007) Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 143(2):223–231PubMedCrossRef de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S et al (2007) Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 143(2):223–231PubMedCrossRef
5.
go back to reference Grinblat B, Scheinberg M (2008) The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthr Rheum 37(4):251–255CrossRef Grinblat B, Scheinberg M (2008) The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthr Rheum 37(4):251–255CrossRef
6.
go back to reference Seneschal J, Milpied B, Vergier B, Lepreux S, Schaeverbeke T, Taïeb A (2009) Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 161(5):1081–1088PubMedCrossRef Seneschal J, Milpied B, Vergier B, Lepreux S, Schaeverbeke T, Taïeb A (2009) Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 161(5):1081–1088PubMedCrossRef
8.
go back to reference Tanghetti EA (2009) The role of topical vitamin D modulators in psoriasis therapy. J Drugs Dermatol 8(8 Suppl):s4–s8PubMed Tanghetti EA (2009) The role of topical vitamin D modulators in psoriasis therapy. J Drugs Dermatol 8(8 Suppl):s4–s8PubMed
9.
go back to reference Arnson Y, Amital H, Shoenfeld Y (2007) Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 66(9):1137–1142PubMedCrossRef Arnson Y, Amital H, Shoenfeld Y (2007) Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 66(9):1137–1142PubMedCrossRef
10.
go back to reference Prabhu Anand S, Selvaraj P, Narayanan PR (2009) Effect of 1, 25 dihydroxyvitamin D3 on intracellular IFN-gamma and TNF-alpha positive T cell subsets in pulmonary tuberculosis. Cytokine 45(2):105–110PubMedCrossRef Prabhu Anand S, Selvaraj P, Narayanan PR (2009) Effect of 1, 25 dihydroxyvitamin D3 on intracellular IFN-gamma and TNF-alpha positive T cell subsets in pulmonary tuberculosis. Cytokine 45(2):105–110PubMedCrossRef
11.
go back to reference Dayangac-Erden D, Karaduman A, Erdem-Yurter H (2007) Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients. Arch Dermatol Res 299(10):487–491PubMedCrossRef Dayangac-Erden D, Karaduman A, Erdem-Yurter H (2007) Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients. Arch Dermatol Res 299(10):487–491PubMedCrossRef
12.
go back to reference Okita H, Ohtsuka T, Yamakage A, Yamazaki S (2002) Polymorphism of the vitamin D(3) receptor in patients with psoriasis. Arch Dermatol Res 294(4):159–162PubMedCrossRef Okita H, Ohtsuka T, Yamakage A, Yamazaki S (2002) Polymorphism of the vitamin D(3) receptor in patients with psoriasis. Arch Dermatol Res 294(4):159–162PubMedCrossRef
13.
go back to reference Perez A, Raab R, Chen TC, Turner A, Holick MF (1996) Safety and efficacy of oral calcitriol (1, 25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 134(6):1070–1078PubMedCrossRef Perez A, Raab R, Chen TC, Turner A, Holick MF (1996) Safety and efficacy of oral calcitriol (1, 25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 134(6):1070–1078PubMedCrossRef
14.
go back to reference Huckins D, Felson DT, Holick M (1990) Treatment of psoriatic arthritis with oral 1, 25-dihydroxyvitamin D3: a pilot study. Arthr Rheum 33(11):1723–1727CrossRef Huckins D, Felson DT, Holick M (1990) Treatment of psoriatic arthritis with oral 1, 25-dihydroxyvitamin D3: a pilot study. Arthr Rheum 33(11):1723–1727CrossRef
15.
go back to reference Gaál J, Lakos G, Szodoray P, Kiss J, Horváth I, Horkay E et al (2009) Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: results of an open, follow-up pilot study. Acta Derm Venereol 89(2):140–144PubMed Gaál J, Lakos G, Szodoray P, Kiss J, Horváth I, Horkay E et al (2009) Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: results of an open, follow-up pilot study. Acta Derm Venereol 89(2):140–144PubMed
Metadata
Title
Resolution of adalimumab-induced psoriasis after vitamin D deficiency treatment
Authors
Gláucio Ricardo Werner de Castro
Fabrício Souza Neves
Ivanio Alves Pereira
Sonia Cristina Magalhaes Souza Fialho
Giovana Ribeiro
Adriana Fontes Zimmermann
Publication date
01-05-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 5/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-1799-9

Other articles of this Issue 5/2012

Rheumatology International 5/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.